Morepen Laboratories Launches Empamore: A Game-Changer in Diabetes Care

Morepen Laboratories Limited has unveiled its latest innovation in the healthcare sector, Empamore, a groundbreaking treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). This strategic move marks a significant expansion of the company's product portfolio, targeting a substantial patient population affected by these chronic conditions.

Addressing India's Diabetes Challenge

With India being dubbed the diabetes capital of the world, boasting over 101 million people suffering from the disease, Empamore's launch comes at a crucial time. The product aims to revolutionize diabetes care by offering a high-quality, affordable treatment option, potentially empowering millions of Indians to better manage their health.

Product Range and Innovation

Empamore's product line includes:

• Empagliflozin (Empamore 10mg/25mg)
• Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)

Empagliflozin, the active ingredient, is a globally recognized SGLT2 inhibitor widely used for diabetes management. Morepen manufactures the API in its USFDA-approved facilities, ensuring top-tier quality and safety standards.

Affordability Meets Quality

In a game-changing move, Morepen is offering Empamore at nearly 90% lower cost than existing brands. This dramatic price reduction aims to make world-class diabetes treatment accessible to a broader segment of the population, addressing a critical healthcare gap in India.

Ashutosh Sharma, V.P. - Sales & Marketing at Morepen Laboratories, emphasized the company's commitment: "At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at a fraction of the cost, helping millions manage their condition effectively without financial strain."

Beyond Diabetes: A Comprehensive Solution

Empamore's benefits extend beyond glycemic control, addressing cardiovascular and renal complications associated with diabetes. This comprehensive approach aligns with the growing need for multifaceted treatments in managing chronic conditions.

Market Impact and Growth Potential

With pre-diabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.90%, Morepen's launch of Empamore is well-timed. The company aims to capture a significant share of this rapidly expanding market, leveraging its 40 years of pharmaceutical excellence and extensive global footprint spanning 82 countries.

Innovation in Patient Care

Empamore stands out not only for its affordability but also for its patient-centric design:

• Comprehensive diabetes solution addressing multiple related conditions
• Global quality standards with USFDA-approved manufacturing
• Innovative packaging with perforated strips for improved patient adherence

Morepen's Legacy in Diabetes Care

This launch builds on Morepen's strong foundation in diabetes management. The company has already installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, demonstrating its commitment to empowering people with "Health in Your Hands".

As Morepen Laboratories continues to innovate and expand its healthcare solutions, the launch of Empamore represents a significant step forward in making quality diabetes care more accessible and affordable for millions of patients in India and potentially worldwide.